Breast Cancer after Mantle Field Irradiation for Hodgkin's Disease
A. Katz, B. Brenner, A. Sulkes, H. Luria, G. Marshak, E. Fenig
Oncology Institute, Rabin Medical Center, Beilinson Campus, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv University
Effective use of modern therapeutic modalities results in the cure of 75%-80% of Hodgkin's disease patients, regardless of stage. The major threat to continued survival is, therefore, not recurrent disease but development of second malignancies. Recent reports have firmly established the increased risk of breast cancer developing in women treated with mantle field irradiation.
We describe 3 women who developed breast carcinoma following mantle field irradiation for Hodgkin's disease. Their clinical course was consistent with that reported in larger series. They were relatively young when irradiated and there was a long interval between radiation therapy and the diagnosis of breast cancer.
Review of the literature shows that there may be a role for prophylactic mastectomy after irradiation for Hodkgin's disease.